Functionality of C-Reactive Protein for Atheroprotection

Frontiers in Immunology
Sanjay K Singh, Alok Agrawal

Abstract

C-reactive protein (CRP) is a pentameric molecule made up of identical monomers. CRP can be seen in three different forms: native pentameric CRP (native CRP), non-native pentameric CRP (non-native CRP), and monomeric CRP (mCRP). Both native and non-native CRP execute ligand-recognition functions for host defense. The fate of any pentameric CRP after binding to a ligand is dissociation into ligand-bound mCRP. If ligand-bound mCRP is proinflammatory, like free mCRP has been shown to be in vitro, then mCRP along with the bound ligand must be cleared from the site of inflammation. Once pentameric CRP is bound to atherogenic low-density lipoprotein (LDL), it reduces both formation of foam cells and proinflammatory effects of atherogenic LDL. A CRP mutant, that is non-native CRP, which readily binds to atherogenic LDL, has been found to be atheroprotective in a murine model of atherosclerosis. Thus, unlike statins, a drug that can lower only cholesterol levels but not CRP levels should be developed. Since non-native CRP has been shown to bind to all kinds of malformed proteins in general, it is possible that non-native CRP would be protective against all inflammatory states in which host proteins become pathogenic. If it is proven th...Continue Reading

References

Feb 1, 1971·Proceedings of the Society for Experimental Biology and Medicine·J E Volanakis, M H Kaplan
Feb 1, 1994·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·S MookerjeaA Nagpurkar
Apr 1, 1996·Nature Structural Biology·A K ShriveT J Greenhough
Feb 6, 1999·Journal of the American College of Cardiology·W H KaesemeyerR W Caldwell
Feb 11, 1999·The New England Journal of Medicine·C Gabay, I Kushner
Apr 9, 1999·Arteriosclerosis, Thrombosis, and Vascular Biology·T BjörnhedenO Wiklund
Oct 16, 1999·Arteriosclerosis, Thrombosis, and Vascular Biology·S BhakdiM Hemmes
Sep 9, 2000·Arteriosclerosis, Thrombosis, and Vascular Biology·M TorzewskiJ Torzewski
Jun 30, 2001·The New England Journal of Medicine·P M RidkerUNKNOWN Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators
Sep 10, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Alok AgrawalDavid Samols
Sep 24, 2002·Proceedings of the National Academy of Sciences of the United States of America·Mi-Kyung ChangJoseph L Witztum
Dec 20, 2002·Nature·Peter Libby
Apr 17, 2004·American Journal of Physiology. Heart and Circulatory Physiology·M Brennan HarrisRichard C Venema
Oct 1, 2004·The Journal of Biological Chemistry·Madathilparambil V SureshAlok Agrawal
Jan 7, 2005·The New England Journal of Medicine·Paul M RidkerUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Inv
Jan 7, 2005·The New England Journal of Medicine·Steven E NissenUNKNOWN Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators
Feb 5, 2005·Arteriosclerosis, Thrombosis, and Vascular Biology·Lambertus van TitsAnton Stalenhoef
Mar 26, 2005·Arteriosclerosis, Thrombosis, and Vascular Biology·Claire ArnaudFrançois Mach
Apr 15, 2005·Molecular Immunology·Alok Agrawal
May 28, 2005·Proceedings of the National Academy of Sciences of the United States of America·Gideon M HirschfieldMark B Pepys
May 28, 2005·Arteriosclerosis, Thrombosis, and Vascular Biology·Kurt ReifenbergSucharit Bhakdi
Jul 9, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Steven BlackDavid Samols
Sep 30, 2005·The American Journal of Pathology·Huijun SunJianglin Fan
Mar 1, 2006·Atherosclerosis. Supplements·Matthias Endres
Jun 23, 2006·Journal of Clinical Pathology·Silja NorjaSirkka Goebeler

❮ Previous
Next ❯

Citations

Apr 1, 2020·Frontiers in Bioengineering and Biotechnology·Carlos A LabarrereGhassan S Kassab
Apr 17, 2020·Frontiers in Immunology·Jian-Min LvBin Cheng
Oct 7, 2019·Prostaglandins & Other Lipid Mediators·Bahar TunctanKafait U Malik
Jul 3, 2021·International Journal of Molecular Sciences·Anastasia V PoznyakAlexander N Orekhov

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic
antisense oligonucleotides
antisense oligonucleotide

Related Concepts

Related Feeds

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.